

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

INSIDE INFORMATION ANNOUNCEMENT
ISSUANCE OF THE FILING NOTICE BY THE CSRC FOR THE H SHARE
FULL CIRCULATION BY THE COMPANY

This announcement is made by TransThera Sciences (Nanjing), Inc. (藥捷安康(南京)科技股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated October 20, 2025 in relation to the proposed implementation of the full circulation of 44,971,128 domestic shares of the Company (the “**Domestic Share(s)**”) held by 10 shareholders of the Company, representing approximately 11.01% of the total issued share capital of the Company as at the date of this announcement (the “**H Share Full Circulation**”).

The board of directors (the “**Board**”) of the Company is pleased to announce that on October 26, 2026, the Company received a filing notice (the “**Filing Notice**”) issued by the China Securities Regulatory Commission (the “**CSRC**”) regarding the Company’s implementation of the H Share Full Circulation. According to the Filing Notice, the Company has completed the filing with the CSRC in respect of the conversion of 44,971,128 Domestic Shares of the Company into H shares of the Company (the “**H Share(s)**”) held by such shareholders. The Filing Notice will be valid for 12 months from the date of issuance of the Filing Notice. The Company will apply to the Listing Committee of the Stock Exchange for the approval of the listing and permission to deal in the relevant H Shares.

As at the date of this announcement, details of the Company’s implementation plan of the H Share Full Circulation and the conversion and listing of relevant shares (the “**Conversion and Listing**”) have not been finalised. The Company will make further announcement(s) on the progress of the Conversion and Listing in compliance with the requirements of the Listing Rules and applicable laws as and when appropriate.

The completion of the Conversion and Listing is subject to fulfilling other relevant procedures as required by the Stock Exchange and other competent regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, October 26, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin as a non-executive director; and (iii) Ms. Chui Hoi Yam, Mr. Feng Weibo and Mr. Li Shu Pai as independent non-executive directors.